Birth defect rates in women using Adalimumab (Humira(®) ) to treat immunologic-based infertility in IVF patients.

American journal of reproductive immunology (New York, N.Y. : 1989)

Volumn 66, Issue 3, 2011, Pages 237-241

  Winger, Edward E ^a   Reed, Jane L ^b   Ashoush, Sherif ^b   El Toukhy, Tarek ^b   Ahuja, Sapna ^b   Taranissi, Mohamed ^b  

^a USA Assisted Reproduction amp Gynaecology Centre   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIINFLAMMATORY AGENT; ENOXAPARIN; INTERLEUKIN 10; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLOOD; CONGENITAL DISORDER; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; HUMAN; PREGNANCY; TH1 TH2 BALANCE;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; CONGENITAL ABNORMALITIES; ENOXAPARIN; FEMALE; FERTILIZATION IN VITRO; HUMANS; INFERTILITY, FEMALE; INTERLEUKIN-10; PREGNANCY; TH1-TH2 BALANCE; TUMOR NECROSIS FACTOR-ALPHA;

MLCS; MLOWN;

EID: 84856137484     PISSN: None     EISSN: 16000897     Source Type: Journal    
DOI: 10.1111/j.1600-0897.2011.00994.x     Document Type: Article

References (0)